Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • US debt crisis: Joe Biden gets the deal done but at a cost
    • White House reaches deal with Republicans to avert US debt default
    • US debt ceiling deadline pushed back as talks continue
    • ‘War over water’: drought battle reaches luxury pools of southern France
    • Saudi Arabia in talks to join China-based ‘Brics bank’
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Sky to cut hundreds of jobs in shift from satellite TV
      • Beverly Hills voters reject LVMH luxury hotel on Rodeo Drive
      • EY US reshuffles leadership following failure of spin-off plan
      • UK mid-market dining chains fight for survival after Covid and cost of living woes
      • Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Weddings and divorce: the scourge of investment returns
      • Investors expect higher interest rates as inflation pressures mount
      • Is COP28 destined to be a flop?
      • AI boom drives gains for chip stocks
      • Flight risk? London listings are the most vulnerable to New York’s allure
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Buffett’s intriguing bet on Japan
      • Weddings and divorce: the scourge of investment returns
      • A stylist, yes, but Martin Amis was also right on the money
      • Letter from the editor on generative AI and the FT
      • The price of flying will keep rising, even on Ryanair
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
      • Germany’s tangled relationship with Russia
      • Economist Daniel Chandler: ‘Shareholders have all the power. It doesn’t have to be that way.’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • GCHQ’s Jeremy Fleming: ‘Xi doesn’t want to see Putin humiliated’
      • The UK’s best bakeries: the readers’ picks
      • From Bowie to Jagger, the photos that created legends
      • Yes, Suella Braverman should go, but not for the reason you think
      • We need to talk about picnics
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Coronavirus treatment

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 26 May, 2023
      Covid-19 vaccines
      Brussels and Pfizer agree deal to cut supply of Covid vaccines

      Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

    • Sunday, 14 May, 2023
      Novavax Inc
      Cash-strapped Novavax urges governments to honour Covid jab deals

      US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic

    • Friday, 12 May, 2023
      Simon Schama
      The thwarting of science will always be a human failing

      From India to Britain, we have always managed to get in the way of our own inventiveness

    • Tuesday, 9 May, 2023
      Janan Ganesh
      The west’s handling of the pandemic beat its own expectations

      A demonised elite produced vaccines and furloughs while a supposedly rebellious public mostly followed the rules

    • Monday, 1 May, 2023
      Noubar Afeyan
      Moderna co-founder calls on US politicians and judges to stop questioning science

      Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases

    • Sunday, 30 April, 2023
      Covid-19 vaccines
      BioNTech/Pfizer’s mooted EU deal for 70mn Covid shots threatens rivals

      European health officials have advocated portfolio diversity to help fight different variants

    • Friday, 28 April, 2023
      Special ReportThe Americas’ Fastest Growing Companies
      Moderna tries to show it’s not a ‘one trick pony’

      Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects

    • Wednesday, 26 April, 2023
      Pharmaceuticals sector
      EU aims to create ‘single market for medicines’ with overhaul of pharma rules

      Revamp that would cut drugmakers’ years of market exclusivity meets fierce opposition from sector

    • Monday, 24 April, 2023
      EU business regulation
      EU outlines plan to take control of medicine production in health crises

      Proposal for compulsory licensing risks ire of pharma groups keen to protect patents and revenue

    • Friday, 14 April, 2023
      UK labour disputes
      Nurses in England to stage biggest strikes yet after rejecting pay offer

      NHS ‘in limbo’ after Royal College of Nursing calls for 48-hour walkout affecting critical care

    • Friday, 31 March, 2023
      Camilla Cavendish
      Sharing patient data is something to be celebrated, not feared

      Easier access to NHS records will save lives — but health executives must make their case to the public

    • Monday, 27 March, 2023
      BioNTech
      BioNTech forecasts slump in sales as demand for Covid jab wanes

      Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

    • Wednesday, 15 March, 2023
      Taiwan
      Taiwan loses diplomatic ally as Honduras confirms link to China

      Central American nation was one of Taipei’s last partners in Washington’s backyard

    • Tuesday, 14 March, 2023
      Covid-19 vaccines
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

    • Tuesday, 7 March, 2023
      Covid-19 vaccines
      UK spring Covid boosters will target elderly and vulnerable

      Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn

    • Friday, 3 March, 2023
      Healthcare
      US health and science bodies unite to fight misinformation ‘infodemic’

      Fifty organisations form coalition to counter dangerous falsehoods and rebuild trust in science

    • Friday, 24 February, 2023
      Special ReportHealth at Work
      Why Long Covid rehab must be very, very slow

      Employers advised they need to offer more time and flexibility compared with other illnesses

    • Tuesday, 21 February, 2023
      Pfizer Inc
      Pfizer pins hopes on record pipeline to recover from post-Covid hangover

      Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs

    • Wednesday, 15 February, 2023
      Jayasree Iyer
      Poor countries desperately need better access to generic medicines

      Manufacturers showed during the pandemic that they can deliver low-cost treatments at scale

    • Wednesday, 15 February, 2023
      Covid-19 vaccines
      CanSino says vaccine demand down after China’s mass Covid infections

      Pharma group hopes for approval of mRNA vaccine for booster shots

    • Thursday, 9 February, 2023
      AstraZeneca PLC
      AstraZeneca chief says industry should not pay for NHS Covid costs

      Pascal Soriot criticises pricing agreement with UK health service

    • Sunday, 29 January, 2023
      Drugs research
      RQ Bio partners with AstraZeneca in Covid antibody fight

      UK biotech racing to keep antibody up to date with latest variants

    • Thursday, 26 January, 2023
      UK universities
      Lack of clinical academics threatens NHS research and teaching, say peers

      Shortage of doctors with university posts is putting health service on ‘dangerous precipice’

    • Tuesday, 24 January, 2023
      Kate Bingham
      Britain is losing its chance to become a life sciences superpower

      Short-termism and suspicion in parts of government risk our valuable future in precision medicine

    • Monday, 23 January, 2023
      News in-depth
      Rural China runs short of Covid drugs over lunar new year holiday

      Officials row with Pfizer over price as villages struggle to obtain antiviral medication

    Previous page You are on page 1 Next page

    Recommended

    Covid-19 vaccines
    Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
    Covid-19 vaccines
    Covid vaccine development: The shots available and the doses administered
    Covid-19 vaccines
    In graphics: the UK vaccine supply chain
    Coronavirus: free to read
    Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In